

IA-IF

wherein: the carbon atom designated * is in the R or S configuration;

R^1 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, OR^9 and $-NR^9R^{10}$;

R^2 is H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl or C_1-C_6 haloalkyl;

R^3 is H, halogen, $-S(O)_nR^{12}$, $-S(O)_nNR^{11}R^{12}$, -CN, $-C(O)R^{12}$, $-C(O)NR^{11}R^{12}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -O(phenyl) or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy, or wherein R^3 is a C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, $-OR^9$ and $-NR^9R^{10}$; provided that for compounds of formula IA, R^3 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, $-OR^9$ and $-NR^9R^{10}$;

provided that for compounds of formula IB, R^3 is -O(phenyl), -O(benzyl), $-OC(O)R^{13}$ or $S(O)_nR^{12}$, each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^4 is H, halogen, $-S(O)_nR^{12}$, $-S(O)NR^{11}R^{12}$, -CN, $-C(O)R^{12}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}R^{12}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -O(phenyl) or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloikyl, or C_1-C_4 alkoxy and wherein R^4 is a C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, $-OR^9$ and $-NR^9R^{10}$; provided that for compounds of formula IC, R^4 is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted; provided that for compounds of formula ID, R^4 is -O(phenyl), -O(benzyl), $-OC(O)R^{13}$, $-NR^{11}R^{12}$ or $-S(O)_nR^{12}$, each of -O(phenyl) and -O(benzyl) being optionally substituted, wherein R^3 and R^4 are not both H;

R^5, R^6 and R^7 in compounds of each of the formulae IA, IB, IC, ID, IE and IF are each independently H, halogen, $-OR^{11}$, $-S(O)_nR^{12}$, -CN, $-C(O)R^{12}$, $-NR^{11}R^{12}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}C(O)_2R^{12}$, $-NR^{11}C(O)NR^{12}R^{13}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, wherein each of R^5, R^6 and R^7 is a C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, $-OR^9$ and $-NR^9R^{10}$, or R^5 and R^6 or R^6 and R^7 may be $-O-C(R^{12})_2-O-$; provided that for compounds of formula IE at least one of R^5 or R^7 is fluoro, chloro, or methyl; or R^5 or R^6 are each independently $-O-C(R^{12})_2-O-$ in compounds of the formulae IE, but only where R^7 is fluoro, chloro or methyl; or R^7 and R^6 can independently also be $-O-C(R^{12})_2-O-$ in compounds of the formulae IE, but only where R^5 is fluoro, chloro or methyl;

R^8 is H or halogen, provided that for compounds of formula IF, R^8 is halogen;

R^9 and R^{10} are each independently H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, $-C(O)R^{13}$, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl,

or C_1-C_4 alkoxy; or R^9 and R^{10} are taken together with the nitrogen to which they are attached to form piperideine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

R^{11} is H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, -C(O)R^{13}, phenyl or benzyl, where R^{11} is a C_1-C_4 alkyl, phenyl or benzyl group, then said group is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^{12} is H, amino, C_1-C_4 alkyl, (C_1-C_4 alkyl)amino, C_1-C_4 haloalkyl, C_1-C_4 alkoxyalkyl, C_3-C_6 cycloalkyl, C_4-C_7 cycloalkylalkyl, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 alkoxy; or R^{11} and R^{12} are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

B1

provided that only one of R^9 and R^{10} or R^9 and R^{10} are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

R^{13} is C_1-C_4 alkyl, C_1-C_4 haloalkyl or phenyl;

n is 0, 1, or 2, and;

aryl is phenyl which is optionally substituted 1-3 times with halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 alkoxy, or

an oxide thereof, or a pharmaceutically acceptable salt thereof, wherein the compound has a binding affinity for dopamine transporter protein to a binding affinity for norepinephrine transporter protein ratio of at least 2:1 and a binding affinity for serotonin transporter protein to a binding affinity for norepinephrine transporter protein ratio of at least 20:1.

52. The compound of claim 51, wherein R^1 is C_1-C_3 alkyl.

53. The compound of claim 52, wherein R^1 is CH_3.

54. The compound of claim 51, wherein R^2 is H, C_1-C_4 alkyl or C_1-C_6 haloalkyl.

55. The compound of claim 54, wherein R^2 is H or CH_3.

56. The compound of claim 51, wherein R^3 is H or R^3 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, -OR^9 and –NR^9R^{10} or R^3 is -O(phenyl) or –O(benzyl) optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

57. The compound of claim 56, wherein R^3 is methyl, ethyl, propyl, or isopropyl.

58. The compound of claim 56, wherein R^3 is -O(phenyl) or –O-CH_2-(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

59. The compound of claim 56, wherein R^3 is H.

60. The compound of claim 51, wherein R^4 is H, or R^4 is –$NR^{11}R^{12}$ or R^4 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted, or wherein R^4 is -O(phenyl) or -O(benzyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

61. The compound of claim 60, wherein R^4 is methyl, ethyl, propyl, or isopropyl.

62. The compound of claim 60, wherein R^4 is -O(phenyl) or –O(CH_2)(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

63. The compound of claim 60, wherein R^4 is H.

64. The compound of claim 51, wherein R^3 and R^4 are each halogen.

65. The compound of claim 51, wherein one of R^3 and R^4 is H and the other is CH_3.

66. The compound of claim 51, wherein R^5, R^6 and R^7 are each H, halogen, $-OR^{11}$, $-NR^{11}R^{12}$, C_1-C_6 alkyl and substituted C_1-C_6 alkyl.

67. The compound of claim 66, wherein R^5, R^6 and R^7 are each H.

68. The compound of claim 66, wherein one of R^5 or R^7 is F, Cl, or Me and the other of R^5 or R^7 and R^6 are H, halogen, $-OR^{11}$, $-NR^{11}R^{12}$, or optionally substituted C_1-C_6 alkyl.

B'

69. The compound of claim 68, wherein R^5 is F, Cl or Me; and R^7 is H.

70. The compound of claim 68, wherein R^5 is F, Cl or Me; and R^6 is H.

71. The compound of claim 51, wherein R^8 is halogen.

72. The compound of claim 71, wherein R^8 is fluoro.

73. The compound of claim 51, wherein:

R^1 is C_1-C_3 alkyl;

R^2 is H, C_1-C_4 alkyl or C_1-C_6 haloalkyl;

R^3 is C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted, or R^3 is –O(phenyl) or –O(benzyl), each of which is optionally substituted, or R^3 is H;

R^4 is H, C_1-C_4 alkyl, C_3-C_6 cycloalkyl or C_4-C_7 cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C_1-C_3 alkyl, halogen, aryl, -CN, $-OR^9$ and $-NR^9R^{10}$, or R^4 is $-NR^{11}R^{12}$, -O(phenyl) or –O(benzyl), wherein said –O(phenyl) or –O(benzyl), is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy.

or R^3 and R^4 are each halogen;

R^5, R^6 and R^7 are each halogen, $-OR^{11}$, $-NR^{11}R^{12}$, optionally C_1-C_6 alkyl, or one of R^5 and R^7 is Cl, F or Me and the other of R^5 and R^7 and R^6 is H, halogen, $-NR^{11}R^{12}$, C_1-C_6 alkyl or substituted C_1-C_6 alkyl.

74. The compound of claim 51, wherein:

R^1 is CH_3;

R^2 is H or CH_3;

R^3 is H, F, methyl, ethyl, propyl, isopropyl, -O(phenyl) or $-O-CH_2-$(phenyl), wherein said –O(phenyl) or $-O-CH_2-$(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^4 is H, F methyl, ethyl, propyl, isopropyl, –O(phenyl) or $-O-CH_2-$(phenyl), wherein said -O(phenyl) or $-O-CH_2-$(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or C_1-C_4 alkoxy;

R^5, R^6 and R^7 are each H or R^5 is F, Cl or Me, or one of R^6 or R^7 is H and the other of R^6 and R^7 is halogen, $-OR^{11}$, $-NR^{11}R^{12}$, or optionally substituted C_1-C_6 alkyl.

75. The compound of claim 73, wherein R^8 is halogen.

76. The compound according to claim 51, wherein the carbon atom designated * is in the R configuration.

77. The compound according to claim 51, wherein the carbon atom designated * is in the S configuration.

78. A composition comprising a mixture of stereoisomeric compounds of claim 51 wherein the carbon atom designated * is in the S or R configuration.

79. The compound according to claim 51, selected from the group consisting of the following compounds:

4-(4-methoxy)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-4-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro-4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro-3-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-dichloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

7-ethyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

B1

4-(3,4-difluoro)phenyl-7-ethyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(3-fluoro-4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(3-fluoro-4-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(4-chloro-3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-cyano-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-4-phenyl-7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;

4-phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;

4-phenyl-2,7,8-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-8-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-7-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-7-phenoxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

7-(4-methoxy)phenoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

7-benzyloxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,5-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-4-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-dichloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro-3-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-methoxy)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-cyano)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-trifluoromethyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,8-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-8-(N-methylamino)methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

8-(hydroxy)methyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

2-methyl-4-phenyl-8-sulfonamide-1,2,3,4-tetrahydroisoquinoline;

B1 2-methyl-8-(N-methyl)sulfonamide-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,5-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-5-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,5-difluorophenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;

(8-fluoro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-N-methylmethanamine;

2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-N-methylmethanamine;

N-methyl(2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-N-methylmethanamine;

(2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinyl)methanol; and

an oxide thereof, or a pharmaceutically acceptable salt thereof.

80. The compound according to claim 51, selected from the group consisting of the following compounds:

	R^1	R^2	R^3	R^4	R^5	R^6	R^7	R^8
1.	Me	H	H	Me	H	OMe	H	H
2.	Me	H	H	Me	H	F	H	H
3.	Me	H	H	Me	F	H	H	H
4.	Me	H	H	Me	F	F	H	H
5.	Me	H	H	Me	Me	F	H	H
6.	Me	H	H	Me	Cl	F	H	H
7.	Me	H	H	Me	Cl	H	H	H
8.	Me	H	H	Me	H	Me	H	H

Sub C2

	R^1	R^2	R^3	R^4	R^5	R^6	R^7	R^8
9.	Me	H	H	Me	F	Me	H	H
10.	Me	H	H	Me	H	Cl	H	H
11.	Me	H	H	Me	F	Cl	H	H
12.	Me	H	H	Me	Cl	Cl	H	H
13.	Me	H	H	Et	H	H	H	H
14.	Me	H	H	Et	F	F	H	H
15.	Me	H	H	F	H	OMe	H	H
16.	Me	H	H	F	F	OMe	H	H
17.	Me	H	H	F	F	Me	H	H
18.	Me	H	H	F	F	Cl	H	H
19.	Me	H	H	F	F	F	H	H
20.	Me	H	H	F	Cl	H	H	H
21.	Me	H	H	CN	H	H	H	H
22.	Me	H	H	CF_3	H	H	H	H
23.	Me	Me	H	Me	H	H	H	H
24.	Me	H	Me	Me	H	H	H	H
25.	Me	H	F	Me	H	H	H	H
26.	Me	H	Me	F	H	H	H	H
27.	Me	H	H	O(Ph)	H	H	H	H
28.	Me	H	H	O(4-OmePh)	H	H	H	H
29.	Me	H	H	$O(CH_2Ph)$	H	H	H	H
30.	Me	H	Me	H	H	F	H	H
31.	Me	H	Me	H	F	F	H	H
32.	Me	H	Me	H	F	H	F	H
33.	Me	H	Me	H	F	H	H	H
34.	Me	H	Me	H	Me	F	H	H
35.	Me	H	Me	H	Cl	F	H	H
36.	Me	H	Me	H	Cl	Cl	H	H
37.	Me	H	Me	H	Cl	H	H	H
38.	Me	H	Me	H	H	Cl	H	H
39.	Me	H	Me	H	F	Cl	H	H
40.	Me	H	Me	H	H	OMe	H	H

Sub C2

B1

R691189.2

	R^1	R^2	R^3	R^4	R^5	R^6	R^7	R^8
41.	Me	H	Me	H	H	CN	H	H
42.	Me	H	Me	H	H	CF_3	H	H
43.	Me	H	Me	H	H	Me	H	H
44.	Me	H	CH_2NHMe	H	H	H	H	H
45.	Me	H	CH_2OH	H	H	H	H	H
46.	Me	H	SO_2NH_2	H	H	H	H	H
47.	Me	H	SO_2NHMe	H	H	H	H	H
48.	Me	H	H	Me	F	H	F	H
49.	Me	H	H	Me	F	H	Cl	H
50.	Me	Me	H	Me	F	H	F	H
51.	Me	H	H	Me	F	F	F	H
52.	Et	H	H	Me	H	F	H	H
53.	Me	H	F	CH_2Me	H	H	H	H
54.	Me	H	H	CH_2NH_2	H	H	H	H
55.	Me	H	H	CH_2NHMe	H	H	H	H
56.	Me	H	H	CH_2OH	H	H	H	H

81. The compound according to claim 51, wherein the enantiomer is selected from the group consisting of the following compounds:

	R^1	R^2	R^3	R^4
1.	Me	H	F	F
2.	Me	F	H	F
3.	Me	H	F	H
4.	Me	H	H	F

82. The compound according to claim 79, which is the (+) stereoisomer.

83. The compound according to claim 79, which is the (-) stereoisomer.

84. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 51.

85. A method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 51, or a pharmaceutically acceptable salt thereof.

86. The method according to claim 85, wherein the disorder is selected from the group: attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, panic attacks, Parkinsonism and phobia, obesity, late luteal phase syndrome or narcolepsy, cocaine addition, amphetamine addiction, and psychiatric symptoms anger such as, rejection sensitivity, and lack of mental or physical energy.

87. A method of inhibiting synaptic norepinephrine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 51.

88. A method of inhibiting synaptic serotonin uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 51.

89. A method of inhibiting synaptic dopamine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 51.

90. The method of claim 85 wherein the (+)-stereoisomer of the compound is employed.

91. The method of claim 85, wherein the (-)-stereoisomer of the compound is employed.

92. The method of claim 85 for treating attention deficit/hyperactivity disorder.